



News Release

FOR IMMEDIATE RELEASE

CONTACT:

Martin Williams, SVP & Chief Business Officer
Dicerna Pharmaceuticals
(617) 621-8097

Caton Lovett
Pure Communications
(910) 509-3975

Dicerna Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference

WATERTOWN, MA, November 26, 2008 – Dicerna Pharmaceuticals, Inc. (www.dicerna.com), a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™, today announced that James Jenson, Ph.D., chief executive officer of Dicerna, will present at the Piper Jaffray 20th Annual Health Care Conference on December 3, 2008 at 2:30 p.m. (EST) at The Palace Hotel in New York, New York.

About Dicerna

Dicerna Pharmaceuticals is a private, venture-backed RNAi-focused biopharmaceutical company developing novel therapeutic agents in multiple disease areas based on its proprietary Dicer Substrate Technology platform. Dicerna is developing novel RNAi-based therapies, and related drug delivery systems, that use an earlier step in the gene silencing process, namely the engagement of the enzyme Dicer, which is a natural initiation point for the RNAi cascade. This approach results in the knockdown of expression of a targeted gene in a way that is highly selective and specific, and demonstrates greater potency and longer duration of action than other RNAi approaches. The Dicer Substrate Technology is based on intellectual property that is both broadly enabling and distinct from other IP in the field. Dicerna is based in Watertown, Massachusetts. For more information, please visit www.dicerna.com.

###